MX2008001506A - Uso de sales de triotropio en el tratamiento de asma severa persistente. - Google Patents

Uso de sales de triotropio en el tratamiento de asma severa persistente.

Info

Publication number
MX2008001506A
MX2008001506A MX2008001506A MX2008001506A MX2008001506A MX 2008001506 A MX2008001506 A MX 2008001506A MX 2008001506 A MX2008001506 A MX 2008001506A MX 2008001506 A MX2008001506 A MX 2008001506A MX 2008001506 A MX2008001506 A MX 2008001506A
Authority
MX
Mexico
Prior art keywords
treatment
tiotropium salts
severe
asthma
persistant asthma
Prior art date
Application number
MX2008001506A
Other languages
English (en)
Spanish (es)
Inventor
Michael Engel
Stefan Richs
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35432680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2008001506(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2008001506A publication Critical patent/MX2008001506A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2008001506A 2005-08-06 2006-08-02 Uso de sales de triotropio en el tratamiento de asma severa persistente. MX2008001506A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05107266 2005-08-06
PCT/EP2006/064958 WO2007017438A1 (en) 2005-08-06 2006-08-02 Use of tiotropium salts in the treatment of severe persistant asthma

Publications (1)

Publication Number Publication Date
MX2008001506A true MX2008001506A (es) 2008-04-07

Family

ID=35432680

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008001506A MX2008001506A (es) 2005-08-06 2006-08-02 Uso de sales de triotropio en el tratamiento de asma severa persistente.

Country Status (16)

Country Link
US (3) US20070032516A1 (enExample)
EP (1) EP1915158A1 (enExample)
JP (1) JP2009504604A (enExample)
KR (1) KR20080039974A (enExample)
CN (1) CN101237872A (enExample)
AR (1) AR055597A1 (enExample)
AU (1) AU2006277968A1 (enExample)
BR (1) BRPI0614394A2 (enExample)
CA (1) CA2617717C (enExample)
IL (1) IL189248A0 (enExample)
MX (1) MX2008001506A (enExample)
NZ (1) NZ566399A (enExample)
RU (1) RU2422144C2 (enExample)
TW (1) TWI409072B (enExample)
WO (1) WO2007017438A1 (enExample)
ZA (1) ZA200800186B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7250426B2 (en) 2002-11-29 2007-07-31 Boehringer Ingelheim Pharma Gmbh & Co Kg Tiotropium-containing pharmaceutical combination for inhalation
WO2007077162A1 (en) * 2006-01-04 2007-07-12 Boehringer Ingelheim International Gmbh Use of tiotropium salts in the treatment of moderate persistent asthma
MX2012005711A (es) * 2009-11-17 2012-10-05 Cipla Ltd Soluciones de inhalacion.
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3931041C2 (de) * 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US5610163A (en) * 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
US5888396A (en) * 1996-12-17 1999-03-30 Perriello; Felix Anthony Bioremediation of pollutants with butane-utilizing bacteria
US6156503A (en) * 1997-03-03 2000-12-05 The Regents Of The University Of California Diagnosing asthma patients predisposed to adverse β-agonist reactions
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
GB0009583D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
CA2425539C (en) * 2000-10-12 2007-04-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Crystalline monohydrate, processes for the preparation thereof and the use thereof for preparing a pharmaceutical composition
US6908928B2 (en) * 2000-10-12 2005-06-21 Bi Pharma Kg. Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
US6919325B2 (en) * 2001-09-14 2005-07-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts
DE10216036A1 (de) * 2002-04-11 2003-10-23 Boehringer Ingelheim Pharma Aerosolformulierung für die Inhalation enthaltend ein Tiotropiumsalz
WO2004014293A2 (en) * 2002-06-12 2004-02-19 Epigenesis Pharmaceuticals, Inc. Combination of anti-muscarinic agents and non-glucocorticoid steroids
EP1531866A1 (en) * 2002-08-29 2005-05-25 Cipla Ltd. Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids
US7968717B2 (en) * 2003-11-03 2011-06-28 Boehringer Ingelhein International Gmbh Crystalline anhydrate with anticholinergic efficacy
SE0303571D0 (sv) * 2003-12-03 2003-12-22 Microdrug Ag Medical product for moisture-sensitive medicaments
SE0303570L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Fukt-känslig medicinsk produkt
AU2006244683A1 (en) * 2005-05-10 2006-11-16 Synergenz Bioscience Limited Methods and compositions for assessment of pulmonary function and disorders
AU2006248189A1 (en) * 2005-05-20 2006-11-23 Synergenz Bioscience Limited Methods of analysis of polymorphisms and uses thereof
US20070167480A1 (en) * 2005-12-19 2007-07-19 Sicor Inc. Pure and stable tiotropium bromide
WO2007077162A1 (en) 2006-01-04 2007-07-12 Boehringer Ingelheim International Gmbh Use of tiotropium salts in the treatment of moderate persistent asthma

Also Published As

Publication number Publication date
NZ566399A (en) 2011-07-29
CA2617717C (en) 2014-02-11
RU2422144C2 (ru) 2011-06-27
TW200744606A (en) 2007-12-16
US20130245059A1 (en) 2013-09-19
WO2007017438A1 (en) 2007-02-15
CA2617717A1 (en) 2007-02-15
RU2008108302A (ru) 2009-09-20
EP1915158A1 (en) 2008-04-30
ZA200800186B (en) 2009-04-29
IL189248A0 (en) 2008-08-07
KR20080039974A (ko) 2008-05-07
US20070032516A1 (en) 2007-02-08
AU2006277968A1 (en) 2007-02-15
BRPI0614394A2 (pt) 2011-03-29
AR055597A1 (es) 2007-08-29
TWI409072B (zh) 2013-09-21
JP2009504604A (ja) 2009-02-05
US20090163531A1 (en) 2009-06-25
CN101237872A (zh) 2008-08-06

Similar Documents

Publication Publication Date Title
MY151048A (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
MX341212B (es) Inhibidor de bromodominio de benzodiazepina.
PL1765349T3 (pl) Opioidy do leczenia przewlekłej obturacyjnej choroby płuc (POChP)
NZ596187A (en) Use of an anti-tau ps422 antibody for the treatment of brain diseases
PH12012500894A1 (en) Benzodiazepine bromodomain inhibitor
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
NZ599928A (en) Use of pentosan polysulfate for treatment or prophylaxis of asthma
MX346186B (es) Inhibidores de proteina cinasas.
IL201479A (en) Use of tapentadol for the preparation of pain medication
NZ616806A (en) Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
MX2009008825A (es) Nuevos metodos de terapia anticolinergica.
MX2012000488A (es) Terapia de combinacion para el tratamiento de la diabetes.
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
TNSN07263A1 (en) Substituted 4-phenyl tetrahydroisoquinolines, methods for producing them, their use as drug, and drug containing them
TWI372056B (en) Novel medicament combinations for the treatment of respiratory diseases
MX2007012538A (es) Uso de lactobacillus gg en la manufactura de un medicamento para la prevencion o tratamiento de alergias respiratorias.
NZ595364A (en) TISSUE KALLIKREIN FOR THE TREATMENT OF PANCREATIC beta-CELL DYSFUNCTION
UA94954C2 (uk) Застосування есцину для лікування хвороби, походження якої опосередковане або викликане активованими гранулоцитами
NO20082439L (no) Anvendelse av tiotropiumsalter for behandling av moderat vedvarende astma
MX2010002032A (es) Uso de flibanserina para el tratamiento de sintomas vasomotores.
MX2008001506A (es) Uso de sales de triotropio en el tratamiento de asma severa persistente.
WO2010004031A3 (en) Treatment of amyotrophic lateral sclerosis by nogo-a-antagonist
WO2011056850A3 (en) Linaclotide for the treatment of chronic constipation
TW200724146A (en) Use of LGG in the manufacture of a medicament for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant

Legal Events

Date Code Title Description
FG Grant or registration